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CONTINUOUS GLUCOSE MONITORING
ABSTRACT
Continuous glucose monitors (CGMs) are used to measure a patient’s glucose levels every few
minutes around the clock. According to the National Institute of Diabetes and Digestive and
Kidney Disease (NIDDK), CGMs are mostly used by Type 1 Diabetes Mellitus patients, but
research has shown that Type 2 DM patients can benefit from them as well (Ida et al., 2019;
NIDDK, 2017). Glucose levels can change over hours or days, and seeing the trends by using a
CGM will help patients make more informed decisions about the food they eat and how much
they exercise, and the type and amount of medication they take (NIDDK, 2021). The use of
CGMs allows more control over a patient’s disease process and promotes better health
maintenance. The final outcome of using CGMs is lowering hemoglobin A1c levels. When
glucose is monitored continuously, trends can be seen, hyperglycemic episodes, which may
require a medication adjustment or an increase in exercise regimen, will be seen. This is
especially beneficial for those who are hypoglycemic unaware, as food or glucose can be given
to bring glucose levels to normal. Each of these adjustments keeps the glucose in the body at a
more stable level, and ultimately, HbA1c levels will become lower as well.
Keywords: Type 2 diabetes, continuous glucose monitoring, hemoglobin A1c, T2DM,
self-monitoring blood glucose, hypoglycemia, adults
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SECTION ONE: FORMULATING THE REVIEW QUESTION
Introduction
One of the greatest concerns with diabetic patients is the damage that high glucose levels
can have on the blood vessels of the body, which could lead to heart disease, stroke, kidney
disease, retinopathy, and neuropathy (National Institute of Diabetes and Digestive and Kidney
Disease [NIDDK], 2021). The outcome of keeping blood sugar levels within normal range can
be seen in evaluation of the hemoglobin A1c (HbA1c) levels. Maintaining time in range (TIR) of
glucose levels by using a continuous glucose monitor (CGM) will ultimately lower HbA1c
levels. The ability to see at a glance if a patient’s glucose level is above range, below range, or in
range will help the patient to be aware of the action needed to keep levels maintained better. The
trends that can be seen with CGMs will allow patients, as well as medical personnel, to provide
better care in that they can see these ranges. Using CGMs in Type 2 diabetes mellitus (T2DM)
patients will allow them a better quality of life and could help them to escape the micro- and
macrovascular problems that are related to glucose levels that are not well controlled. A review
of numerous articles demonstrated that the use of CGMs benefits adult patients who have T2DM
by lowering their HbA1c levels.
Problem Statement
This integrative review (IR) addresses the following clinical statement: In T2DM adult
patients, the use of CGMs will improve the TIR of glucose levels, thus leading to a reduction of
HbA1c levels.
Background
Continuous glucose monitoring is the use of a small sensor applied under the skin in the
upper arm or abdomen that detects the glucose levels in the interstitial fluid (the fluid between
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the cells). Most CGMs can detect the glucose levels every one to five minutes and show a trend
or pattern over a 24-hour period or longer (NIDDK, 2017). Most patients who are diagnosed
with T2DM check their blood sugar levels via self-monitoring blood glucose (SMBG) methods
three to four times daily. Using SMBG addresses glucose levels at certain points in time, such as
at meals and at bedtime. By using CGMs instead, patients and providers alike can see trends in
glucose levels and make management decisions accordingly. With better management of glucose
levels, HbA1c levels will be lower, thus decreasing the probability of the development of comorbidities such kidney disease, heart disease, blindness, and neuropathy (Ida et al., 2019).
In the United States, according to the Centers for Disease Control (2019), 26 million
people have a diagnosis of T2DM, and another 79 million have prediabetes. Ida et al. (2019)
presents some astounding numbers from the World Health Organization, which estimated that
the number of people with T2DM may increase to over 300 million by the year 2050. Arguello
and Freeby (2017) stated that there have been many advances in the treatment in T2DM over the
past several decades, but over half of patients are still not controlling their glucose levels, which
creates more risk for further complications. It is important to know that diabetes management is
not viewed in a silo, that is, it is not a disease that can be viewed as just one problem.
Uncontrolled diabetes is responsible for the leading causes of blindness, kidney disease, heart
disease, neuropathy, foot complications, high blood pressure, and stroke (American Diabetes
Association, n.d.). The use of CGMs can help assist patients and care providers to better manage
the disease, thus lowering the incidences of these other issues as well. In other words, CGMs
may lead the way for prevention of secondary diseases associated with T2DM. Type 2 diabetic
patients who use real-time CGMs have a way to look back and make adjustments to their
lifestyle and pharmacotherapy regimen based on data (Ida et al., 2019). As mentioned earlier,
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most CGMs are used by Type 1 diabetes mellitus (T1DM) patients. This brings up the question
of why? Approximately 90%–95% of diabetics in the United States have T2DM, with the
remainder having T1DM (Centers for Disease Control, 2019). Patients with both types of
diabetes need to know their glucose levels, know their trends, keep their glucose under control,
and avoid associated diabetes-related diseases. Compared to SMBG in T2DM patients, CGMs do
not pose such a burden on these patients, such as the painful finger sticks that are associated with
SMBG (Ida et al., 2019). Providers and patients alike need to see the importance of using CGMs
as a tool for controlling the disease in both types of diabetes. For millions of patients with
uncontrolled T2DM, CGMs can make a difference by facilitating better control of glucose levels,
thereby decreasing the complications associated with the disease.
Defining Concepts and Variables
The keywords used for this IR were: Type 2 diabetes, continuous glucose monitoring,
hemoglobin A1c, T2DM, self-monitoring blood glucose, hypoglycemia, and adults. For the
purpose of this review, continuous glucose monitoring is conceptually defined as a glucose
monitoring system that can track glucose levels at any time, day and night, and provides a way to
see trends at a glance (NIDDK, June 30, 2021). Continuous glucose monitoring is operationally
defined for this IR as the device used to manage glucose levels for the purpose of lowering
Hemoglobin A1c levels. Hemoglobin A1c is conceptually defined as the amount of blood sugar
(glucose) attached to hemoglobin for the past three months. Other names for hemoglobin A1c
include HbA1c, A1c, glycol-hemoglobin, glycated hemoglobin, and glycosylated hemoglobin.
Operational definition of Hemoglobin A1c in this IR is the laboratory result after T2DM patients
use continuous glucose monitoring to manage their diabetes.
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In identifying a topic for this IR, the reviewer chose a topic of interest that “stimulated
curiosity and is meaningful to the reviewer and the profession” (Toronto & Remington, 2020, p.
14). The topic of CGMs is important to this reviewer because of the large number of people
suffering with diabetes daily. Type 2 diabetics should be able to control their glucose levels by
seeing their real-time glucose levels, giving them the opportunity to make decisions that will
help lower their HbA1c levels. Carlson et al. (2017) explained that CGMs can be used as a “tool
to help personalize a diabetes treatment plan” (p. S4). Knowledge of the trends of a patient’s
glucose levels also provides the health care provider with the information needed to present
optimal treatment options for the diabetic patient.
Rationale for Conducting the Review
The purpose of this IR was to critique and review the literature to uncover what is known
about T2DM patients who use CGMs and whether there is evidence of lower HbA1c levels as a
result of the use of a CGM. This IR answers the “who, what, when, why and where” questions
suggested by Toronto and Remington (2020, p. 16). CGMs use a small sensor inserted under the
skin to track interstitial glucose levels automatically on a 24-hour basis (NIDDK, 2017). The
monitor can be used alone or in combination with an insulin pump. Many CGMs have special
features that allow the user to set alarms for high and low glucose levels and download data to a
computer or a smartphone to view trends more easily. The monitors are used to see trends over a
few hours or a few days. Although most CGMs are worn by patients with T1DM, evidence
shows that T2DM patients can benefit from using them as well (Ajjan et al., 2019; Carlson et al.,
2017). CGMs give real-time data to help those with T1DM and T2DM view their glucose trends
at a glance. Having the ability to know their glucose level and see trends allows patients to make
the needed exercise, dietary, or treatment changes and ultimately reduce their HbA1c levels
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(Carlson et al., 2017). According to Sherwani et al. (2016) and Carlson et al. (2017), the HbA1c
test is now the standard of care in diagnosing and monitoring T2DM patients. If this test is used
in combination with CGMs, significant improvement can be seen in these patients (Azhar et al.,
2020; Carlson et al., 2017). Given the high prevalence of T2DM and the comorbidities
associated with it, CGMs can play a role in reducing many disease-related complications. This
IR presents published evidence on the relationship between the use of CGMs and lower HbA1c
levels. This IR lays the groundwork for changes in the care management of T2DM patients.
Health care providers may use the nursing science and information associated with this IR to
make more informed decisions and achieve better health outcomes for Type 2 diabetic patients.
Type 2 diabetics may use this IR to play a larger role in self-management of their disease.
Purpose or Review Question
The purpose for this IR was to review the literature published from 2015 to 2021 to help
determine if there is a relationship between the use of CGMs and lower HbA1c levels in adults
with T2DM. Type 2 diabetics check their blood sugar levels at random throughout the day,
normally around meals and at bedtime, which allows these patients to see what their blood sugar
level is only at that point in time. With CGMs, these same patients can, at a glance, see what
their glucose levels are every one to five minutes, as well as see the trend of their levels
throughout the day (Reddy et al., 2020). The ability to see trends in glucose levels allows
patients who are diagnosed with T2DM to make adjustments in their diet, exercise plans, and
medication regimen (Carlson et al., 2017). Reddy et al. (2020) supported this adjustment in
behavior by saying, “Use of CGM can help both the patient and their medical provider make fine
tune adjustments to medication therapy and provide insight to the patient on behavioral changes
to achieve glycemic control” (p. 3). Practitioners can use this data to better manage T2DM
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patients by seeing these trends via computer and making more insightful decisions regarding
medication dosages and diet plans (Carlson et al., 2017; Ida et al., 2019). In the end, integrating
CGMs into T2DM patients’ health management plan will help patients and providers alike to
maintain better control over glucose levels and achieve better health outcomes of lower HbA1c
levels, thereby decreasing other related health issues that are inevitable when glucose levels are
constantly high.
This project purposed to analyze and synthesize information from articles describing the
outcomes of the use of CGMs in T2DM patients. This research is significant because most
CGMs are used by T1DM patients at this time but are also beneficial in the management of
T2DM patients as well (Anders et al., 2017). Based on the evidence regarding the impact of the
use of CGMs on HbA1c levels in Type 2 diabetics, the use of CGMs is proposed to play a vast
role in health management of these patients.
The IR addresses the following clinical statement: In T2DM adult patients, the use of
CGMs as compared to random blood sugar checks will help increase the TIR of glucose levels,
thus leading to a reduction of HbA1c levels. The following questions helped support and focus
the review process:
1) How are patient outcomes affected by using CGMs, particularly HbA1c levels?
2) What factors contribute to health care providers’ use of CGMs in T2DM patients?
3) When using CGMs in T2DM patients, is TIR positively effected?
Inclusion and Exclusion Criteria
It is with a clear review question that the reviewer is able to develop inclusion and
exclusion criteria for studies located through the literature search (Toronto & Remington, 2020).
In order to maximize the number of resources for this literature review, a systematic search was
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conducted by using these databases: CINAHL, PubMed, ProQuest, and Medline. The keywords
used in the search were: continuous glucose monitors, hemoglobin A1c, Type 2 diabetes, selfmonitoring blood glucose levels, adults, and glucose management outcomes. The search results
were narrowed to include only articles written between the years of 2015 and 2021, peerreviewed journal articles, full-text articles, and articles written in the English language. The
disciplines that were used as search criteria were nursing, medicine, and public health.
Newspaper articles, dissertations, and book reviews were excluded from the original search.
Literature Search Results
After applying inclusion criteria and searching using the term continuous glucose
monitoring, results showed 12,906 articles. After adding the terms hemoglobin A1c and Type 2
diabetes mellitus, 2,470 articles were found. Next, the results were narrowed to only include
articles containing such terms as adults and outcomes, hypoglycemia, and self-monitoring of
blood glucose, and 286 articles remained. Studies included in the review focused on Type 2
diabetics using CGM devices and the effects of the use of the CGM on HbA1c levels. After
adding the exclusion criteria of pregnancy, children, Type 1 diabetes, specific technology
companies, retinopathy, and oral anti-glycemic, 57 articles resulted from the search. After
articles that were duplicates or did not meet the criteria for this IR were removed, the remaining
19 studies spoke directly to Type 2 diabetes management and reduction of HbA1c through the
use of CGMs.
An analysis of the articles retrieved revealed that some did not meet the criteria to answer
the research question. Articles were also excluded that only addressed barriers to using CGMs
and how to access them. Others were excluded because they only addressed gestational diabetes
and CGMs, focused on children and adolescents, or only studied T1DM. Articles were chosen
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for inclusion if they related entirely to CGMs and the lowering of HbA1c levels (Azhar et al.,
2020; Chehregosha et al., 2019; Cowart et al., 2020; Haak, 2018; Hajime et al., 2018; Ida et al.,
2019; Janapala et al., 2019; Mariani et al., 2017; Taylor et al., 2018; Toschi & Wolpert, 2016;
Vigersky & Shrivastav, 2017; Yeoh et al., 2018). Other articles contain supporting information
regarding other outcomes of using CGMs such as increased TIR and glycemic efficacy, and
decreased hypoglycemic events and may be used to further increase the evidence level of this IR
(Battelino et al., 2019; Carlson et al., 2017; Gomez-Peralta et al., 2020; Haak, 2018; Ida et al.,
2019; Ishikawa et al., 2018; Mohan et al., 2016; Park & Le, 2018; Torimoto et al., 2017; Yeoh et
al., 2018). Still other articles were chosen because they focused on Type 2 diabetics who are
using insulin along with CGMs and may be useful in further research (Beck et al., 2017;
Ishikawa et al., 2018).
Articles chosen included randomized controlled trials (RCT), descriptive/qualitative
studies, systematic reviews, meta-analyses of RCTs, and quasi-experimental controlled trials.
The articles selected included several Level 1 and 2 evidence articles, according to the Melnyk &
Fineout-Overholt (2015) framework, and several studies used large number of participants,
factors which strengthen this IR. However, a few of the studies did not show enough data to
support of the IR or the length of the study was not long enough to provide accurate data. HbA1c
levels take longer than 30 days to show results (normally 90 days), and any study conducted in
less time would not prove strong enough to support this IR.
The articles chosen for this IR were ones that give strength to the clinical question of
whether using CGMs in adults with T2DM has an effect on HbA1c levels. In the past, the use of
CGMs was assessed only with T1DM patients but has more recently been shown useful in
T2DM patients, especially those T2DM patients who take insulin (Reddy et al., 2020). The
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usefulness of CGMs is seen in lower HbA1c, which in turn decreases the risk of secondary
diabetes-related conditions such as kidney disease, retinopathy, hypoglycemia events, and
peripheral nerve damage.
Conceptual Framework
The conceptual framework used for this IR served to connect all aspects of the review
(Toronto & Remington, 2020). Whittemore and Knafl (2005)’s research on IRs was used as the
framework for this IR. Using this framework allowed the inclusion of current information that
addressed the issues specific to the review question. The stages included in this conceptual
framework to conduct this IR were: identifying the problem, searching the literature, evaluating
the data, analyzing the data, and presenting the results (Whittemore & Knafl, 2005).
Whittemore and Knafl (2005) suggested that the problem be clearly identified so the
reader knows clearly what the IR addresses. The problem should also include the target
population and the health care problem, T2DM adult patients in this IR. In the literature search
stage, Whittemore and Knafl (2005) recommended that the writer include the search methods,
such as databases used or hand searches. Data evaluation should include empirical and
theoretical sources used in the search for literature. Data analysis includes data reduction, data
display, data comparison, and conclusion drawing (Whittemore & Knafl, 2005). The last stage of
the framework described by Whittemore and Knafl (2005) is presentation. Primary source details
and evidence that gives the reader assurance that there is a logical chain of evidence within the
review should be presented during this stage.
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SECTION TWO: COMPREHENSIVE AND SYSTEMATIC SEARCH
Search Organization and Reporting Strategies
Maximum resources for this IR were obtained through a systematic search approach
using these databases: CINAHL, PubMed, ProQuest, and Medline. These platforms included
comprehensive databases for nursing research and information that contained peer-reviewed
articles from science journals with full-text availability (Toronto & Remington, 2020). The
keywords used in the search were: continuous glucose monitors, hemoglobin A1c, Type 2
diabetes, self-monitoring blood glucose levels, glucose management, and outcomes. The search
was narrowed by setting parameters for articles published between 2015 and 2021, articles that
were peer reviewed, and articles written in the English language. Discipline criteria were also set
to include nursing, medicine, and public health. Excluded from the search were newspaper
articles, dissertations, and book reviews.
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA),
(Appendix C) was the reporting model used to show the flow of information through the
different phases of the review (Toronto & Remington, 2020). The methodology used to search
was comprehensive, and more than one database was searched in order to locate the most
information possible about the use of CGMs and its relationship to HbA1c levels. This
methodology also helped to minimize bias and increase the rigor of the study.
Terminology
The term database, as used in this IR, referred to the electronic, searchable collection of
published materials which included professional journals that were peer-reviewed (Toronto &
Remington, 2020). The term search engine referred to a library search of multiple databases
using Liberty University’s Jerry Falwell library. Databases used were Medline, PubMed,
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CINAHL plus with full text, ProQuest’s Health and Medical Collection, Journal of the American
Medical Association, and ProQuest’s Nursing and Allied Health Database (Toronto &
Remington, 2020).
SECTION THREE: MANAGING THE COLLECTED DATA
The initial step during the review involved evaluating the titles and abstracts of the
articles that resulted from the search for relevancy to the review topic. Articles were not
discarded if they did not exactly match the eligibility criteria but were discarded if they were
related to T1DM, children, or pregnancy. Abstracts of the articles were read and used to locate
relevant information regarding CGMs and their relationship to HbA1c levels. Articles were also
selected based on whether they included full text. These articles were stored and sorted into
categories in a Word document provided by this author (see Appendix B). Studies that were
described in more than one report were counted as one study, but both reports were used to
collect data about this IR project (Toronto & Remington, 2020). A visual representation of the
screening and selection process was created using the PRISMA flowchart (Moher et al., 2009).
The PRISMA flowchart depicts the process of obtaining data and articles, including the numbers
of articles included and excluded (see Appendix D).
SECTION FOUR: QUALITY APPRAISAL
Sources of Bias
This IR used the PRISMA framework (Moher et al., 2009). The flowchart developed for
this study helped to reduce the possibility of ensuring the focus was not too narrow and reduced
bias accordingly. This IR serves to educate clinicians in the area of their specialty, which in this
case is T2DM, and reducing bias is necessary for this process. During the review of the article
topics and themes for this IR, there was no evidence of bias. Reducing bias is necessary for
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clinicians to use this IR as a place to start when clinical practice guidelines are developed (Moher
et al., 2009).
Internal Validity & External Validity
It is important to reduce bias to keep from compromising the validity of the results of the
IR (Toronto & Remington, 2020). In order to achieve internal validity, the study results should
be as near to the truth as possible (Toronto & Remington, 2020). The methods used to obtain
results for this IR also provide validity to this study. External validity will assist in the critical
appraisal of this IR in that the results will be applied to those who have T2DM and who use
CGMs, which is the population of interest. Some may suggest that internal validity, or
“believability,” is just as important in the critical appraisal of the IR as the external validity
(Toronto & Remington, 2020, p. 48).
Appraisal Tools (Literature Matrix)
Health care workers use critical appraisal tools to look at and evaluate evidence. These
tools may include checklists or structured questions, but there is no gold standard for which tool
to use. Therefore, using a common, familiar tool such as a literature matrix is recommended
(Buccheri & Sharifi, 2017). The tool used to appraise the quality of the included studies of this
IR was a literature matrix using the Melynk model to evaluate the levels of evidence. The
Melynk model was used to appraise and rank the power of each article. Melynk’s (Melnyk &
Fineout-Overholt, 2015) levels of evidence include Levels I through VII, with Level I being the
strongest. Level I incudes systemic reviews and meta-analyses of RCTs. Level II includes
articles that consist of one or more RCTs. Level III articles are controlled trials with no
randomization. If an article includes case-controlled or cohort studies, it is considered Level IV.
Articles containing systematic review of descriptive and qualitative studies are Level V, and
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single descriptive or qualitative studies are considered Level VI. And finally, Level VII articles
are expert opinions on the subject of continuous glucose monitoring (Melnyk & FineoutOverholt, 2015).
Applicability of Results
The articles chosen were relevant to the question for this IR. In order to support the
credibility of the data analysis and findings of the studies used, results were entered into the
literature matrix (Toronto & Remington, 2020). The literature matrix was used to critically
appraise the study purpose, sample (including characteristics of the sample), methods used in the
study, study results, level of evidence using the Melnyk framework (Melnyk & FineoutOverholt, 2015), limitations of the study, and the ability to use the article to make a change.
Reporting Guidelines
The approach used to review data about CGM is the IR method. Whittemore and Knafl
(2005) stated that the “integrative review method is the only approach that allows for the
combination of diverse methodologies” (p. 546). This IR includes methodologies of both
experimental and nonexperimental research. Future evidence-based practice initiatives for
nursing will depend on these different types of methodologies (Whittemore & Knafl, 2005).
SECTION FIVE: DATA ANALYSIS AND SYNTHESIS
Data Analysis Methods
It was important to note that comparing data across studies is pertinent to conducting an
IR and increases the rigor of this review (Toronto & Remington, 2020). The approach used was
development of literature matrix to separate the article information into categories (Appendix B).
The method used in this IR was a constant comparison method, which Whittemore and Knafl
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(2005) described as having four phases: data reduction, data display, data comparison, and
conclusion drawing and verification.
Data Reduction
The data from the articles retrieved were reduced and simplified through a search for
themes and categorization of those themes. The enormous amount of information within these
articles needed to be reduced to an amount that could be managed more easily. The project
leader could then sort through the data for relevance and significance to be confident in the
consistency of the review (Whittemore & Knafl, 2005). Along with the review questions,
recommendations from the Centers for Disease Control regarding people other than T1DM
patients who may benefit from CGMs were used to support and focus this review. Some of these
groups who may benefit from the use of CGMs are: (a) people with T2DM who are receiving
intensive insulin therapy, (b) people who have T2DM who are not meeting their glycemic targets
and are not on insulin therapy, and (c) people who have T2DM who have hypoglycemia
unawareness or frequent hypoglycemia episodes (American Diabetes Association, 2020). These
categories were used to focus the search for articles.
Data Display
For the purpose of this review, the articles were displayed in a literature matrix (evidence
table) which shows the title of the articles, authors, study purpose, sample, methods, study
results, level of evidence, limitations, and use of the study (Appendix E). Data were then
compressed and displayed in a matrix showing the articles that fit into each of the categories
(Appendix B). The visual display of a matrix allows the reader to see the relationships and
patterns within the literature (Whittemore & Knafl, 2005).
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Data Comparison
The literature categories table (Appendix B) depicts themes and patterns as well as
relationships between articles (Whittemore & Knafl, 2005). The categories found more
abundantly in the literature were those that pertained to the relationship between CGMs and
HbA1c levels or between TIR and CGMs. Also seen was the association of CGMs with the
identification of hypoglycemia events. Another category that was shown quite often was the use
of CGMs by those who are on insulin therapy.
Conclusion Drawing and Clarification
The article matrix and category matrix (table) were used during this study to identify the
results of the review. During this phase, the articles were reviewed again to confirm truthfulness
and also to show where there were similarities in the studies (Whittemore & Knafl, 2005).
Themes of Articles
There were three main themes found in the articles chosen for this IR. They are: (a)
clinical improvement in T2DM HbA1c levels, (b) CGM, insulin users, and T2DM, and (c)
effects of CGM use on HbA1c and TIR.
Clinical Improvement in T2DM HbA1c Levels
Thirteen of the articles obtained for this IR showed that with the use of CGMs, there was
improvement in HbA1c levels. Azhar et al. (2020) showed evidence that T1DM and T2DM
patients had improvement in their HbA1c levels when using CGMs. Three articles showed a
decrease in HbA1c levels when they the use of CGMs was compared to SMBG (Chehregosha et
al., 2019; Janapala et al., 2019; Taylor et al., 2018). In a systematic review of nine RCTs, Cowart
et al. (2020) showed that there was a decrease in HbA1c levels in T2DM patients who use
CGMs. Haak (2018) conducted a 24-week RCT of T2DM patients using CGMs and concluded
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that there was a reduction of HbA1c levels to 7.7% compared to the control of 8%. A
correlational study by Hajime et al. (2018) showed a correlation between the use of a CGM and
lower pre-breakfast glucose levels therefore lower HbA1c levels as well. A systematic review of
literature (meta-analysis) conducted by Ida et al. (2019) determined that time in hypoglycemia is
and HbA1c levels are decreased when patients use CGMs. Toschi and Wolpert (2016) also
maintained that the use of CGMs improves glycemic control and decreases the risks of
hypoglycemic events. Mariani et al. (2017) demonstrated that if T2DM patients using a CGM
start with an HbA1c level greater than 9%, their levels are decreased by their use of the CGM.
Vigersky and Shrivastav (2017) conducted a systematic review of RCTs and provided evidence
of a decrease in HbA1c levels of greater than 0.61% when patients used professional CGMs. In a
retrospective study conducted by Mohan et al. (2016) it was found that when patients who had
average HbA1c levels of 8%–10% used a CGM, mean A1c levels dropped from 8.6% to 8%.
Still another retrospective study of RCTs studying CGM use by chronic kidney disease patients
with T2DM showed that HbA1c levels were decreased after three months, and hyperglycemic
episodes were decreased only after six weeks of use (Yeoh et al., 2018).
Continuous Glucose Monitors, Insulin Users, and T2DM
This category includes evidence that T2DM patients who use CGMs may lower their
HbA1c levels. In a 24-week RCT of 158 T2DM patients who use insulin, the CGM group
lowered their HbA1c levels from 8.5% to 7.7% (Beck et al., 2017). In another single descriptive
study by Ishikawa et al. (2018), 170 T2DM insulin-dependent patients were able to see their
trends and lower their risks for hypoglycemia.
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Effects on HbA1c and Time in Range
Besides the outcome of lowering of HbA1c levels, TIR is also addressed within the
articles reviewed. Battelino et al. (2019) conducted a systematic review of 18 RCTs to show that
there is a relationship between TIR and decreased HbA1c levels. TIR was seen to consistently
lower HbA1c levels in each RCT. In another systematic review of RCTs, Carlson et al. (2017)
found that after 12 weeks of using CGMs in real time, participants’ mean HbA1c levels
decreased by 1% compared to those who did not use CGMs. At 52 weeks, there were similar
results, even without the addition of any medication or any additional hypoglycemic effects. In a
retrospective RCT of 30 chronic kidney disease patients using CGMs, TIR increased after six
weeks, time in hyperglycemia decreased, and HbA1c levels decreased after three months (Yeoh
et al., 2018). In one cohort study, 54 patients with T2DM were educated about the use of CGMs
before they were discharged from the hospital. At 12 weeks after discharge, all the patients’
HbA1c levels were lower (Torimoto et al., 2017). Park and Le (2018) conducted a correlational
study of RCTs involving 1,384 T2DM patients using CGMs and found a relationship between
use of the device and lower HbA1c. One study focused on the use of flash glucose monitoring,
which does not show trends, but shows glucose levels whenever patients scan the device. In 20
RCTs with 22,949 patients, results showed that more frequent scans were correlated with
increased TIR and lower HbA1c levels, averaging 6.9% (Gomez-Peralta et al., 2020).
Descriptive Results
All of the articles obtained for this literature review are were published between 2015 and
2021. The use of this date range helped to maintain the accuracy of this review through the use
of the latest and most updated research information. Matrices were used to organize the data
collected, and information was sorted to show categories and the relationship between lower
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HbA1c levels and the use of CGMs. Using a matrix helps display the evidence in order to assist
the reader see the results clearly (Toronto & Remington, 2020). The data collected show that
CGMs can be used in T2DM patients to lower HbA1c levels and increase the TIR, therefore
protecting them from the harmful effects of hyperglycemia. There is also information that shows
that the use of CGMs lowers the incidence of hypoglycemic events.
Synthesis
Each of the articles for this IR was not individually described in detail in the IR but rather
synthesized within themes that were developed during the data analysis stage. These themes
were presented as a table, and columns were used to show the articles that fell within the
different categories. One category comprised articles that showed a relationship between CGMs
and lower HbA1c levels (Azhar et al., 2020; Chehregosha et al., 2019; Cowart et al., 2020; Haak,
2018; Hajime et al., 2018; Ida et al., 2019; Janapala et al., 2019; Mariani et al., 2017; Mohan et
al., 2016; Taylor et al., 2018; Toschi & Wolpert, 2016; Vigersky & Shrivastav, 2017; Yeoh et al.,
2018). Another theme seen within the literature involved TIR and hypoglycemia, as several
studies showed that using a CGM helps keep glucose levels in range (Battelino et al., 2019;
Carlson et al., 2017; Gomez-Peralta et al., 2020; Haak, 2018; Ida et al., 2019; Ishikawa et al.,
2018; Mohan et al., 2016; Park & Le, 2018; Torimoto et al., 2017; Yeoh et al., 2018).
Additionally, several articles addressed T2DM patients who used insulin therapy and CGMs
(Beck et al., 2017; Ishikawa et al., 2018). These articles all showed a relationship between CGMs
and lower HbA1c.
Ethical Considerations
This project was submitted to the Liberty University Institutional Review Board and an
email was received stating that this project was exempt from any ethical issues. After the email
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from the Institutional Review Board was received, it was archived in a file of the researcher’s
choosing and included as an appendix for the final project write-up (Appendix F). The researcher
then continued to develop this project.
SECTION SIX: DISCUSSION
Implications for Research/Practice/Education
A priority for future research can be the identification of barriers to using CGMs.
Additionally, there is meager evidence on the use of CGMs in the hospital setting. Toronto and
Remington (2020) stated that gaps in the literature such as these need to be identified in order to
set priorities for future studies.
The data reviewed in this study clearly show and support that CGMs need to be used for
T2DM patients, especially those who use insulin, who are prone to hypoglycemic episodes, who
are hypoglycemic unaware, or who are not meeting their glycemic targets (i.e., HbA1c levels
and/or TIR) (ADA, 2020). The information reviewed in this IR shows that keeping TIR by using
CGMs and identifying glucose levels at a glance have a direct correlation to lowering HbA1c.
Educational implications are also warranted considering the results of this review. The use of
CGM data in medical practice for those with T2DM will assist the patient to have increased
activity levels, make better food choices, and better manage hypoglycemic and hyperglycemic
events. Controlling glucose levels by using CGMs will result in lower HbA1c levels.
Dissemination
The information reviewed in this IR is helpful to shape policy and practice to improve
care for patients with diabetes. The practice audience for this review are those health care
workers who address the needs of T2DM patients as well as T2DM patients themselves. The
intent for dissemination for this IR is to spread information from the review to the targeted
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audience through the use and distribution of materials. Distribution of materials to clinicians will
help spread the information, as will writing an article for a nursing magazine. Poster
presentations can also be conducted in formal or informal conferences within health care
settings, although these are older approaches. New approaches should be used as well, such as
the use of news media or social media (Toronto & Remington, 2020).
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Appendix B
Categories Matrix Table for Literature Related to CGMs
Clinical Improvement in
T2DM HbA1c levels
Azhar, A., Gillani, S. W.,
Mohiuddin, G., & Majeed,
R. A. (2020).

Chehregosha, H., Khamseh,
M. E., Malek, M.,
Hosseinpanah, F., & IsmailBeigi, F. (2019).
Cowart, K., Updike, W. &
Bullers, K. (2020).
Haak T. (2018).
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Mori, H., Otsuka, T.,
Kawaguchi, M., Miyazaki,
M., Kuno, F., Sugai, K.,
Sonoda, S., Tanaka, K.,
Kurozumi, A., Narisawa, M.,
Torimoto, K., Arao, T., &
Tanaka, Y. (2018).
Ida, S., Kaneko, R., &
Murata, K. (2019).
Janapala, R. N., Jayaraj, J.
S., Nida, F., Tooba, K.,
Norina, U., Amulya, D.,
Nusrat, J., & Issac, S. (2019).
Mohan, V., Jain, S.,
Kesavadev, J., Chawla, M.,
Mutha, A., Viswanathan, V.,
Saboo, B., Kovil, R., Mithal,
A., Punatar, D., & Shin, J.
(2016).
Mariani, H. S., Layden, B.
T., & Aleppo, G. (2017).

CGM, Insulin Users, &
Type 2 DM
Beck, R. W., Riddlesworth,
T. D., Ruedy, K., Ahmann,
A., Haller, S., Kruger, D.,
McGill, J. B., Polonsky,
W., Price, D., Aronoff, S.,
Aronson, R., Toschi, E.,
Kollman, C., & Bergenstal,
R. (2017).
Ishikawa, T., Koshizaka,
M., Maezawa, Y.,
Takemoto, M., Tokuyama,
Y., Saito, T., & Yokote, K.
(2018).

Effect on HbA1c and TIR
Carlson, L., Mullen, D., &
Berrgenstal, R. (2017).
Gomez-Peralta, F., Dunn, T.,
Landuyt, K., Xu, Y., &
Merino-Torres, J. F. (2020).
Mohan, V., Jain, S.,
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Battelino, T., Danne, T.,
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A., Beck, R., Biester, T., Bosi,
E., Buckingham, B. A.,
Cefalu, W. T., Close, K. L.,
Cobelli, C., Dassau, E.,
DeVries, J. H., Donaghue, K.
C., Dovc, K., Doyle, F. J.. III.,
Garg, S., Grunberger, G.,
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Appendix C
Timeline
Action Item
Abstract page
Introduction
Background
Problem statement
Purpose of the project
Clinical question
Inclusion/exclusion criteria
Review of literature
Conceptual framework
Methodology
Evaluation, analysis,
dissemination
Sources of bias
Internal validity
Appraisal tools
Applicability of results
Significance/implications for
practice
Reporting guidelines
Descriptive results
Synthesis
Dissemination of results
References
Appendices

Action

Anticipated Date of
Completion
June 19, 2021 revised

Make sure to include a brief
summation of the project results and
relevance to practice
Check to make sure that the relevance June 19, 2021 revised
to Advanced Nursing Practice is
Included
June 19, 2021 revised
Address the importance for the need
May 23, 2021
for change
Check that the Purpose includes what May 23, 2021
is the significance of the project
May 23, 2021
Add references: in text
June 19, 2021 revised
Make sure that this section is
June 19, 2021 revised
comprehensive vs. exhaustive
Completed
Completed
Complete the results of analysis of
June 7, 2021
data
Completed
Completed
Completed
Continue to develop
June 7, 2021
Include how the results of the project June 7, 2021
influence nursing practice
Include how the results provide new
and fresh insights into CGMs
Continue to develop
June 7, 2021
Continue to develop
June 7, 2021
Continue to develop
June 19, 2021 revised
Continue to develop
June 7, 2021
Make sure that all cited literature is
June 7, 2021
on the reference page and in APA
order
PRISMA
June 19, 2021 revised
Add IRB approval documentation
Put CITI information in
Update Literature Matrix as indicated

CONTINUOUS GLUCOSE MONITORING

38

Appendix D
PRISMA 2009 Flow Diagram

Note. Adapted from “Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA
Statement,: by D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, & The PRISMA Group, 2009, PLoS Med, 6(7):
Article e1000097. (https://doi.org/10.1371/journal.pmed1000097)
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Matrix/Evidence Table

Article
Azhar, A., Gillani, S. W.,
Mohiuddin, G., & Majeed,
R. A. (2020). A systematic
review on clinical
implication of continuous
glucose monitoring in
diabetes management.
Journal of Pharmacy &
Bioallied Sciences, 12(2),
102–111.
https://doi.org/10.4103/jpbs.
JPBS_7_20
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clinical
implication of
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because it
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and Type 2
DM
patients
with
outcomes
of lowering
HbA1c
levels.
TIR was
Level 1
Dual interest This article
shown to
in authors
provides
informatio
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A., Cefalu, W. T., Close, K.
L., Cobelli, C., Dassau, E.,
DeVries, J. H., Donaghue,
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J.. III., Garg, S.,
Grunberger, G., Heller, S., .
. . Phillip, M. (2019).
Clinical targets for
continuous glucose
monitoring data
interpretation:
recommendations from the
international consensus on
time in range. Diabetes
Care, 42(8), 1593–1603.
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Beck, R. W., Riddlesworth,
T. D., Ruedy, K., Ahmann,
A., Haller, S., Kruger, D.,
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Aronson, R., Toschi, E.,
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R. (2017). Continuous
glucose monitoring versus
usual care in patients with

Study
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Sample

Range (TIR)
to HbA1c
levels when
using CGMs

including 18
RCT’s

This was a
RCT to
determine
effects of
CGM on
Adults with
Type 2 DM
who were
receiving
Insulin. This

158
participants
who had DM
Type 2 for at
least 17
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Average age
was 60, with
a mean

Methods

Study
Results

Level of
Evidence

Study
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control
trial

The need for Yes.. This
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study
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the results
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HbA1c

complement
HbA1c

CGM
group and
Control
group were
randomly
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Control
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This study
supports
better
management
of HbA1c
levels by
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The CGM
group
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Use as
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to Support
a Change?
n that will
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reader to
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Study
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Sample

Methods

Study
Results

Level of
Evidence

Study
Limitations

type 2 diabetes receiving
multiple daily insulin
injections: A randomized
trial. Annals of Internal
Medicine, 167(6), 365–374.
https://doi.org/10.7326/M16
-2855

study lasted
24 weeks.

HbA1c level
of 8.5%.

and CGM
used CGM
monitoring
an average
of 6.7 days
per week
for 24
weeks.

HbA1c levels
to a mean of
7.7%
compared to
8..5% at the
beginning of
the study.

Carlson, A. L., Mullen, D.
M., & Bergenstal, R. M.
(2017). Clinical use of
continuous glucose
monitoring in adults with
Type 2 diabetes. Diabetes
Technology & Therapeutics,
19(Suppl. 2), S4–S11.

The article
looks at the
benefits of
CGM’s in
T2DM
patients in a
12 week study

Systematic
review of
severy
RCT’s: 104
patients

SR of
RCT’s

After 12
Level 1:
weeks ther
SR of
was a
RCT’s
derease of
1% in
HbA1c levels
compared to
those who
did not use
CGM

None

Chehregosha, H., Khamseh,
M. E., Malek, M.,
Hosseinpanah, F., & IsmailBeigi, F. (2019). A view
beyond HbA1c: Role of
continuous glucose
monitoring. Diabetes

This article
looks at the
advantages
and
limitations of
using CGM as
a standard in

This article
describes
statistics and
data from
previous
studies.

Descriptive
design

Results show
data that is
associated
with using
CGM and
relays the
effects of

Limitations
is that it a
very small
descriptive
study.

Level 6:
single
descriptiv
e study

Would
Use as
Evidence
to Support
a Change?
levels,
leading to
better ways
to manage
care but is
mainly
used with
patients
that use
Insulin.
Yes. This
study has
much
evidence to
show a
relationshi
p between
CGMs and
lowering of
HbA1c
levels
Yes. with
limited
informatio
n since the
article is
based on a
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Sample

Therapy: Research,
Treatment and Education of
Diabetes and Related
Disorders, 10(3), 853–863.
https://doi.org/10.1007/s133
00-019-0619-1
Cowart, K., Updike, W. &
Bullers, K. (2020).
Systematic review of
randomized control trials
evaluating glycemic
efficacy and patient
satisfaction of intermittentscanned continuous glucose
monitoring in patients with
diabetes. Diabetes
Technology & Therapeutics,
22(5), 337–345.
http://doi.org/10.1089/dia.2
019.0345

assessment of
Diabetes
related
outcomes.
To provide an
updated
analysis of the
efficacy and
patient
satisfaction of
isCGM in
patients with
type 1
diabetes
mellitus
(T1DM) and
type 2
diabetes
mellitus
(T2DM).

Nine
randomized
control trials
were
included in
this
systematic
review.

Gomez-Peralta, F., Dunn,
T., Landuyt, K., Xu, Y., &
Merino-Torres, J. F. (2020).
Flash glucose monitoring
reduces glycemic variability

Purpose is to
show that
flash glucose
monitoring
improves

20 equal
groups of N=
22, 949

Methods

Study
Results

Level of
Evidence

Study
Limitations

Level 1:
Systemati
c Review
of RTC’s

Does not
provide
information
for patients
who are on
insulin or
oral
antidiabetics
.

Yes. This
study will
be useful in
distinguishi
ng the
usage of
CGM in
Type 2
patients.

HbA1c levels Level 2:
were lowest
20 RTC’s
in the highest
scan group at
6.9%.

Only
diabetic
patients
receiving
insulin were

Yes. Given
the
evidence of
lowering

lower HbA1c
levels
compared to
SMBG.
Studies
were
identified
for
assessing
efficacy
and use of
isCGMs in
patients
with
T1DM and
T2DM by
using
Pubmed,
Cochrane
library, and
EMBASE.
Randomize
d Control
Trials

Would
Use as
Evidence
to Support
a Change?
very small
study.

Evidence
shows that
using
Intermittent
CGM may
lower
Hemoglobin
A1C levels
in certain
subgroups.
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Purpose
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Sample

and hypoglycemia: Realglycemic
world data from Spain. BMJ control.
Open Diabetes Research &
Care, 8(1), Article e001052.
https://doi.org/10.1136/bmj
drc-2019-001052

Haak, T. (2018).
Continuous glucose
monitoring versus usual
care in patients with type 2
diabetes receiving multiple
daily insulin injections.
Annals of Internal
Medicine, 168(7), 525–526.
https://doi.org/10.7326/L170705

This study
aimed to show
the
effectiveness
of CGM and
the amount of
decrease in
HgbA1c
levels at 24
weeks.

158 patients
in 25
different
enocrinology
practice
across North
America.
Each patient
had a mean
HgbA1c
level of
8.5%.

Methods

Study
Results

Frequent
scan of flash
glucose
monitoring
increases the
rate of
glucose TIR,
and
decreases
time in hypo
and
hyperglycem
ia.
Experiment The patients
al design
receiving
using
CGM
random
lowered their
assignment HgbA1c
with 79
levels to a
patients
mean of
receiving
7.7% while
CGM and
the control
79 patients group
in the
lowered
control
theirs to 8%.
group.

Level of
Evidence

Study
Limitations
included in
the study.

Level 3:
Randomi
zed
control
trial

The study
was limited
because it
require a 6
month
follow-up
for HgbA1c
levels.

Would
Use as
Evidence
to Support
a Change?
HbA1c
levels.

This is a
strong
article that
will give
evidence to
the study
by showing
a
correlation
of CGM
and a
decreased
A1c level.
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Article
Hajime, M., Okada, Y.,
Mori, H., Otsuka, T.,
Kawaguchi, M., Miyazaki,
M., Kuno, F., Sugai, K.,
Sonoda, S., Tanaka, K.,
Kurozumi, A., Narisawa,
M., Torimoto, K., Arao, T.,
& Tanaka, Y. (2018).
Twenty‐four‐hour variations
in blood glucose level in
Japanese type 2 diabetes
patients based on
continuous glucose
monitoring. Journal of
Diabetes Investigation, 9(1),
75–82.
https://doi.org/10.1111/jdi.1
2680
Ida, S., Kaneko, R., &
Murata, K. (2019). Utility
of real-time and
retrospective continuous
glucose monitoring in
patients with type 2 diabetes
mellitus: A meta-analysis of
randomized controlled
trials. Journal of diabetes
research, 2019, 4684815.

Study
Purpose
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Sample

Methods

Study
Results

Level of
Evidence

Study
Limitations

To evaluate
the
relationship
between
CGMs and
HbA1c levels
in Type 2
diabetics

294 patients
with Type 2
diabetes

Correlation
al design
controlled
trial

Mean
glucose level
and pre‐
breakfast
blood
glucose level
were
significant
and
independent
determinants
of HbA1c.

Level 4

Short study:
2-3 days

Investigation
of effects of
CGM on
weight,
glucose
levels, BP,
and
hypoglycemia
in T2DM
patients.

7 RCT’s with Literature
669 patients
search of 7
with T2DM. RCT’s
searching
the
effectivene
ss of using
CGM’s

CGM in
patients with
T2DM could
help reduce
HbA1c levels
and decrease
the amount
of time in
hypoglycemi
c episodes.

Level 1:
Metaanalysis
of RTC’s

Less than 10
RCT’s need
a funnel
plot. There
was an
increased
risk of bias.

Would
Use as
Evidence
to Support
a Change?
Yes, but
very
limited
because of
the length
of study.

Yes. This
study
would be
useful in
that it
addresses
the
hypoglyce
mic
episode
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Sample

Methods

Study
Results

Level of
Evidence

Study
Limitations

https://doi.org/10.1155/2019
/4684815

Ishikawa, T., Koshizaka,
M., Maezawa, Y.,
Takemoto, M., Tokuyama,
Y., Saito, T., & Yokote, K.
(2018). Continuous glucose
monitoring reveals
hypoglycemia risk in
elderly patients with type 2
diabetes mellitus. Journal of
Diabetes Investigation, 9(1),
69–74.
https://doi.org/10.1111/jdi.1
2676

Identifying
CGM and
relationship of
hypoglycemic
episodes.

170 patients
older than 65
who have
T2DM
receiving
medications
were grouped
to show the
relationship
in using
CGM and
hypoglycemi
c risks

Descriptive
study to
show
relationship
between
CGM and
hypoglyce
mic risks

CGM shows
that
hypoglycemi
c risk are
greater in
those who
are taking
insulin
injections

Level 6:
Single
descriptiv
e study.

Small single
study, risk
of problems
with
calibration
of CGM.

Janapala, R. N., Jayaraj, J.
S., Nida, F., Tooba, K.,
Norina, U., Amulya, D.,
Nusrat, J., & Issac, S.

Systematic
literature
search of
Metanalysis

CGM can
reduce
glycated
hemoglobin

Systematic
review &
meta
analysis

CGM’s in
T2DM prove
to be
beneficial in

Level 1

The
literature
search was
conducted

Would
Use as
Evidence
to Support
a Change?
reduction
as well as
decreasing
HbA1c
levels.
Yes.
Although
this is a
lower level
of study, it
could still
be used to
provide
strength to
the IR
showing a
relationshi
p in how
CGM can
assist in
seeing
trends in
hypoglyce
mia
Yes. The
level of
evidence,
length and
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Article
(2019). Continuous glucose
monitoring versus selfmonitoring of blood glucose
in type 2 diabetes mellitus:
A systematic review with
meta-analysis. Cureus,
11(9), Article e5634.
https://doi.org/10.7759/cure
us.5634
Mariani, H. S., Layden, B.
T., & Aleppo, G. (2017).
Continuous glucose
monitoring: A perspective
on its past, present, and
future applications for
diabetes management.
Clinical diabetes: A
publication of the American
Diabetes Association, 35(1),
60–65.
https://doi.org/10.2337/cd16
-0008

Study
Purpose
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Sample

of RCT’s for
Type 2
diabetic
patients who
use CGM’s

(HbA1c),
hypoglycemi
c events, and
increase
patient
satisfaction

This article
looks at the
clinical
benefits of
using CGM,
including
lowering
HbA1c levels.
It provided
data about the
accuracy in
CG
monitoring
systems.

Looks at data
from other
studies to
provide
information
on outcomes
for CGM.

Methods

Study
Results

Level of
Evidence

lowering
hbA1c levels
when
compared to
SMBG

This article
is more of
opinions of
experts
who are
using other
studies for
data.

There is
evidence of
using CGM
to lower
HbA1c
especially if
their levels
begin at >9

Study
Limitations
only in one
electronic
database,
Medline
(PubMed)
database.

Level 67: More
of expert
opinions

Possible
conflict of
interest with
one of the
authors
receiving
research
money from
Dexcom.

Would
Use as
Evidence
to Support
a Change?
size of the
study give
strength to
this study.

Yes, but
very
limited due
to expert
opinion
and much
data is
about the
accuracy of
the CGM
systems.
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Article

Study
Purpose
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Sample

Methods

Study
Results

Mohan, V., Jain, S.,
Kesavadev, J., Chawla, M.,
Mutha, A., Viswanathan,
V., Saboo, B., Kovil, R.,
Mithal, A., Punatar, D., &
Shin, J. (2016). Use of
retrospective continuous
glucose monitoring for
optimizing management of
type 2 diabetes in India. The
Journal of the Association
of Physicians of India,
64(4), 16–21.

To provide
information
about CGM
and pattern
which can
help
practitioners
with
determining
interventions
and care for
Type 2
diabetics.

A 3 month
study of
Type 2
diabetics
with an A1C
between 8
and 10%.
148
participants
completed
the study.

Questionair
es were
used at
each follow
up visit of
5 different
visits.

CGM shows
that there
was a change
in one
therapy after
month 1 of
the study and
after 3
months,
mean A1c
levels were
from 8.6% to
8%.

Park, C., & Le, Q. A.
(2018). The effectiveness of
continuous glucose
monitoring in patients with
type 2 diabetes: A
systematic review of
literature and meta-analysis.
Diabetes Technology &
Therapeutics, 20(9), 613–
621.

The
effectiveness
of CGM on
HgbA1c in
T2D patients

1384 patients
with T2DM
using CGM
& 4902
patients with
T2DM using
Flash glucose
monitoring

Correlation
al design
comparing
patients
using CGM
& flash
glucose
monitoring.

Results show
that CGM
are effective
in lowering
HbA1c. No
conclusive
results for
flash glucose
monitoring.

Would
Use as
Level of
Study
Evidence
Evidence Limitations
to Support
a Change?
Level 3:
This study is Although
Controlle limited in
Level 3,
d trial,
time, since
this study
Quasiexp A1c levels
may give
erimental may need to significant
design
be repeater
amount of
and this
evidence
study was
that CGM
only 3
may lead to
months in
better
length.
control
because of
the
changes
that may be
made to
treatment
regimens.
Level 1:
This study
Yes. This
Systemat did not
study
aic
address
would
review & safety issues provide
metaor costgreat
analysis
effectivenes informatio
of
s of using
n of 7 RCT
RCT’s.
CGM’s.
studies to
address
CGM’s
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Study
Results

Level of
Evidence

Study
Limitations

11 studies
included 8
RCT’s, and
3
observation
al trials

CGM
promoted
greater
reductions in
glycemic
control
(HbA1c)

Level 1:
Systemati
c review
of RTC’s

High
compliance
is needed to
have better
outcomes.

Single
cohort
study

CGMs
Level 4
helped to
Cohort
identify a
Study
relationship
between of
MBG levels
at discharge
and 12 weeks
after
discharge
with a lower
result in
HbA1c.

Sample

Methods

5,542
participants
were
included in
11 studies,
the mean age
was 51.7-60.

https://doi.org/10.1089/dia.2
018.0177
Taylor, P. J., Thompson, C.
H., & Brinkworth, G. D.
(2018). Effectiveness and
acceptability of continuous
glucose monitoring for type
2 diabetes management: a
narrative review. Journal of
Diabetes Investigation, 9(4),
713–725.
https://doi.org/10.1111/jdi.1
2807
Torimoto, K., Okada, Y.,
Sugino, S., & Tanaka, Y.
(2017). Determinants of
hemoglobin A1c level in
patients with type 2 diabetes
after in‐hospital diabetes
education: A study based on
continuous glucose
monitoring. Journal of
Diabetes Investigation, 8(3),
314–320.
https://doi.org/10.1111/jdi.1
2589

Discusses the
role of CGM
in glycemic
control

Studied
54 patients
patients who
with T2DM.
were educated
about CGMs
before
discharge and
12 weeks later
to see the
difference in
A1c levels

Single study
with small
cohort.

Would
Use as
Evidence
to Support
a Change?
and effects
on HbA1c
levels.
Yes. The
level of
evidence is
high with a
very large
participant
number.

Yes.
Shows a
relationshi
p between
HbA1c
levels and
CGMs
after 3
months.
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Vigersky, R., & Shrivastav,
M. (2017). Role of
continuous glucose
monitoring for type 2 in
diabetes management and
research. Journal of
Diabetes and its
Complications, 31(1), 280–
287.
https://doi.org/10.1016/j.jdi
acomp.2016.10.007
Toschi, E., & Wolpert, H.
(2016). Utility of
continuous glucose
monitoring in type 1 and
type 2 diabetes.
Endocrinology and
Metabolism Clinics, 45(4),
895–904.
https://doi.org/10.1016/j.ecl.
2016.06.003
Yeoh, E., Lim, B. K., Fun,
S., Tong, J., Yeoh, L. Y.,
Sum, C. F., Subramaniam,
T., & Lim, S. C. (2018).
Efficacy of self-monitoring
of blood glucose versus

Study
Purpose
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Sample

Methods

Addressed
evidence for
use of CGMs
in patients
with T2DM,
hypoglycemic
events
discovered,
and
improvement
of glycemic
control
To discuss the
role CGM has
on glycemic
control in
Type 1 & 2
diabetics

Summary of
previous
studies,
RTCs

Summary
of previous
RTC’s

To look at
outcomes of
using CGM
on Type 2
diabetic
kidney

Thirty
patients with
HbA1c >8%
: 14 patients
were in the
CGM group

Endocrinolog
y and
metabolism
clinics of
North
America

Randomize
d control
trial,
retrospectiv
e study

Study
Results

Level of
Evidence

Study
Limitations

Five
randomized
controlled
trials showed
that 3–7 days
of
professional
CGM results
in
improvement
in HbA1C
(0.6%–2.3%)
CGM
improved
glycemic
control and
decreased
hypoglycemi
a risks

Level 1:
Systemati
c Review
of RCT’s

Very good
evidence
from
previous
studies

Level 6:
Expert
Opinion

Level 6

Percentage of
HbA1c levels
in the CGM
groups
decreased
more after 3

Level 2:
RTC
Retrospe
ctive

Small study
groups.

Would
Use as
Evidence
to Support
a Change?

Yes. This
is a high
level of
evidence
and will
show a
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Article
retrospective continuous
glucose monitoring in
improving glycaemic
control in diabetic kidney
disease patients.
Nephrology, 23(3), 264–
268.
https://doi.org/10.1111/nep.
12978

Study
Purpose
disease
patients.

50

Sample
and 16
patients were
placed in the
SMBG
group.

Methods

Study
Results
months, as
well as time
in
hyperglycem
ia decreased
after 6
weeks.

Level of
Evidence

Study
Limitations

Would
Use as
Evidence
to Support
a Change?
relationshi
p between
HbA1c
levels and
CGM’s.
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